[온코크로스] [Bloomberg] Oncocross Begins Clinical Trial for AI-Developed Drug for Sarcopenia
- 작성자온코크로스
- 작성일자
- 조회267
(2022년 2월 25일 기사)
Oncocross Begins Clinical Trial for AI-Developed Drug for Sarcopenia
Business Wire
SEOUL, South Korea -- February 25, 2022
Oncocross, an AI-based drug development biotech, announced that it initiated a
phase I global clinical trial for ‘OC514’ targeting muscular diseases
including sarcopenia.
Oncocross obtained Australia’s Therapeutic Goods Administration (“TGA”)
approval on phase I IND application for OC514 on February 14, 2022 and began a
clinical trial with healthy adults in Australia on February 23, 2022. The
clinical study aims to evaluate the safety, pharmacokinetics, and
pharmacodynamics of OC514.
Sarcopenia is a disease characterized by progressive loss of skeletal muscle
mass and strength, thereby deteriorating normal physical function. Previously,
sarcopenia was considered as a condition that occurs due to aging or other
diseases, but it was designated as an independent disease condition by the
10^th version of an International Classification of Disease (“ICD”) code in
2016. Accompanied by aging, cancers, and other chronic diseases, sarcopenia
lowers the quality of life by weakening overall physical function while
worsening the prognosis of the disease. Currently, there is no approved
treatment for sarcopenia, thus, is considered as a disease with high unmet
medical needs.
Upon completion of phase I, Oncocross plans to conduct phase II clinical
trials for OC514, targeting cancer patients accompanying sarcopenia. The
company said that OC514 could be one of the world’s fastest AI drugs in
development since there are no AI drugs in phase II clinical study to date.
“As a medical oncologist, I saw many cancer patients in a terminal condition
or under chemotherapy also suffering from sarcopenia and I felt a strong need
for a sarcopenia treatment,” said Dr. Yi Rang Kim, CEO of Oncocross. “OC514
has a significant meaning for us since it is one of the first AI-driven drug
candidates for sarcopenia that is going into clinical trials globally. OC514
also demonstrated its efficacy for age-related sarcopenia and rare diseases
such as ALS, also known as Lou Gehrig’s disease, and Duchenne muscular
dystrophy, in various animal models. We will do our best to develop new drugs
that can help numerous patients who are suffering from the diseases.”
About Oncocross
Oncocross is an AI-based drug development biotech based in Seoul, Korea.
Established in 2015, the company developed transcriptome data-based AI
platforms and develops its own pipelines and collaborates with pharmaceutical
companies. Oncocross’s main proprietary AI platforms are RAPTOR AI™, a new
drug development platform and ONCO-RAPTOR AI™ that identifies optimal
indications of anticancer drugs and companion diagnostic biomarkers. The
company is currently collaborating with several pharmaceutical companies,
including Daewoong Pharmaceutical, ST Pharm and 4P-Pharma.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20220225005119/en/
Contact:
Oncocross Co., Ltd.
Daniel Kim
+82-2-867-9967
daniel.kim@oncocross.com